Steve founded MVM Life Science Partners in 1997. Prior to setting up MVM, he was responsible for early-stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 Steve was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor of Medicine and Genetics. He has published more than 50 papers on the molecular genetics of human disease.

Steve has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. He practiced medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas’s Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. He has a degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.

Steve is a member of the boards of Ambio, Inc., Cheetah Medical, Inc., Providence Medical Technology, Inc., Pulmagen Therapeutics Ltd and Zipline Medical, Inc. He was previously a director of Beacon Endoscopic Ltd, BioVex Group, Inc., Cara Therapeutics, Inc., Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals, Inc., New Chemical Entities, Inc., Nova Science Ltd, Sangamo Biosciences, Inc., UpToDate, Inc., Xention Ltd and Vascular Pathways, Inc.

Bob White joined EW as an Operating Partner in 2019 after nearly 30 years leading early-stage companies and Fortune 500 business units in the medical technology sector, including most recently as President and CEO of Entellus Medical, an EW portfolio company acquired by Stryker for ~$660 million.

Mr. White has played a key role in furthering EW’s medical device investment practice. He served on the Board of Directors for Cardiva Medical before it was acquired by Haemonetics, currently serves on the Board of Vital Connect and as the Executive Chairman of the Board of TissueTech.

As mentioned, prior to EW Mr. White was President and Chief Executive Officer of Entellus Medical, driving the business to treat over 250,000 patients suffering from chronic sinusitis, Eustachian tube dysfunction and airway obstruction. In 2018 Mr. White was recognized as a finalist of the Ernst & Young Entrepreneur of the Year and he received the YPO Global Innovation Award.

Prior to Entellus, Mr. White was the President and Chief Executive Officer of TYRX, Inc. which specialized in commercializing innovative, implantable combination drug and device products focused on infection control until TYRX was acquired by Medtronic in 2014. Along the way TYRX was named to the Fierce Medical Devices “Fierce 15”, designating it as one of the leading medical device and diagnostic companies.

Before joining TYRX, Mr. White held several executive positions with Medtronic including serving as President of Physio Control, Vice President of Commercial Operations of the Cardiac Rhythm Disease Management business, and President of Kyphon following Medtronic’s acquisition of the spinal treatment business. Earlier in his career, he held leadership positions in business development, international sales and marketing, operations, and general management with Instromedix/Life Watch, Eli Lilly, IVAC/Alaris Medical, and General Electric.

Mr. White currently also serves as a Director on the Board of Atricure Inc. (NASDAQ: ATRC) and Director on the Board of privately held Cardiac Dimensions Pty. Ltd. Two other companies for which he actively served as a Director were acquired for significant premiums including Novadaq Technologies and privately held Hyperbranch Medical Technology.

Mr. White holds a Bachelor of Science degree in Aerospace Engineering from the University of Missouri-Rolla and a Master of Business Administration degree from Cornell University.

Peter brings more than 20 years of experience in the medical device and biopharmaceutical industry.

Prior to VCI, Peter served as the U.S. commercial vice president at Cordis.  In addition, Peter has held senior sales roles at St. Jude Medical Corporation, AGA Medical Corporation and Covidien Healthcare (formerly Tyco Healthcare), among other leading health care companies.

Peter has proven experience driving commercial growth; building and leading diverse organizations of over 300 individuals, managing revenues exceeding $500 M and representing product offerings with C-level administrators. Peter received a Bachelor of Arts in Economics from the University of Massachusetts and completed the Columbia University Executive Management Program

Nersi is a world class information and medical technologist with 37 years of experience in bringing life changing technologies to widespread commercial use. Nersi has also made contributions to the Medical and Information Technology worlds as an entrepreneur, a CEO and a venture capitalist.

Nersi has brought new communication standards and semiconductor solutions to market including Gigabit local area networking (LAN), WiFi and digital mass storage as well as designing highly integrated System-on-Chip (SoC) solutions.  Hundreds of millions of these parts are in use today and have brought 10’s of billions of dollars of revenue to NASDAQ:MRVL where he pioneered these technologies as the founding vice president of Signal Processing Technology.

After 24 years of purely tech achievements, Nersi founded VitalConnect in 2011 to bring these technologies to digital healthcare by developing the world’s leading patient monitoring solution.  VitalConnect’s VitalPatch®  and Vista Solution® benefit from his expertise in semiconductor chip and SoC design, high volume manufacturing, electronics, signal processing, machine learning, AI and cloud computing.

Nersi has and is serving in several public, private and nonprofit boards. He earned a doctorate in electrical engineering from the University of Colorado and has been awarded nine U.S. patents.

George B. Moore is a partner of Juniper Investment Company, a New York-based private investment firm that invests as an active, long-term, lead shareholder in a concentrated portfolio of US public equity securities. Juniper’s healthcare investments have included Artivion (AORT), Transcat (TRNS) and Theragenics.

Mr. Moore has over 25 years of public and private equity investing experience. During this time has been responsible for sourcing, due diligence, investment approval, execution, value-add and board oversight of numerous public and private company investments. This experience includes extensive transactional expertise, including mergers and tuck-in acquisitions, IPOs, debt and equity offerings, and bank financings. Prior to joining Juniper, Mr. Moore was a partner of Quilvest Private Equity, managing partner of Bristlecone LLC, vice president of Hoak Capital and analyst at Citicorp Venture Capital. Mr. Moore received his B.A. from Colby College and his M.B.A. from Columbia Business School.

Getz currently holds the position of Executive Vice President and Chief Financial & Operations Officer of Butterfly Network Inc. (NYSE: BFLY), a digital health company that is transforming care with handheld, whole-body ultrasound where she is responsible for all aspects of the company’s financial, investor relations, human relations, communications, supply chain, legal and compliance functions.  For the twelve years prior to Butterfly Networks, Getz was the Chief Financial Officer and Administrative Officer of BioTelemetry until 2021 when the company was sold to Royal Philips for $2.8 billion.  She has also held leadership positions at VIASYS Healthcare, Cardinal Health, Alita Pharmaceuticals, Healthy.io. Getz is also a member of the Board of Directors at MYOMO, Inc where she is the Chair of the Audit Committee.

Getz holds a Master of Business Administration and a Bachelor’s degree in accountancy from Villanova University. She is a certified public accountant (inactive) and a member of the National Association for Corporate Directors (NACD),  American Institute of Certified Public Accountants (CPAs),  and the National Investor Relations Institute (NIRI).

Steven Plachtyna is a Vice President at Ally Bridge Group. He joined the firm in 2020 contributing across both the public equity and private equity strategies. Before joining Ally Bridge Group, Steven was a Senior Research Associate at Citi and BMO Capital Markets covering Medical Technologies. Steven began his career at Covidien in Research and Development and holds a BS in Biomedical Engineering from the University of Connecticut, as well as both a M.Eng. in Biomedical Engineering and MBA from Cornell University.

Eric is a Venture Partner at Revelation Partners. He brings multiple decades of experience in healthcare as an investor and scientist. At Revelation Partners he focuses on identifying and leading new investment opportunities with an emphasis on biopharma and medical devices.

Prior to Revelation Partners Eric was a Partner at DCVC Bio where he led investments in early-stage biotechnology companies. Previously, he was a Partner at Novo Ventures where he established and managed the firm’s public equities strategy focused on smidcap and late-stage private companies in therapeutics and medical devices. Earlier in his career Eric was a Director at Apposite Capital focused on healthcare secondaries and an Associate at Burrill & Company, a life sciences venture capital firm. Having initially trained as a structural biologist, he served as a Leukemia & Lymphoma Society Post-Doctoral Fellow.

Eric received a B.A. in Biophysics from the Johns Hopkins University and a Ph.D. in Molecular Biology from Princeton University. Outside of work, Eric enjoys spending time with his wife and three children, rooting for the Texas Longhorns and training for whatever race is next weekend.

Thomas A. Saunders III was president of Ivor & Co., LLC and the Ivor Foundation, a private investment firm and family foundation respectively.

He began his investment banking career at Morgan Stanley where he was a managing director, headed the firm’s syndicate and capital market group and ultimately became Chairman of its $2.2 billion private equity fund. After leaving Morgan Stanley in 1989, he founded the private equity firm, Saunders Karp & Megrue, which merged in 2005 with Apax Partners, LP, a private equity firm headquartered in London.

An active private equity investor, Mr. Saunders was a Senior Advisor to a number of investment funds including Metalmark Capital, Citi’s Old Lane Funds, Roundtable Partners, Parallel Partners, Goode Holdings and Blackrock‘s private equity fund of funds. In addition, he served on the Boards of Directors of the publicly traded Dollar Tree, Inc., where he was Lead Director, and Hibbett Sporting Goods, Inc.

Mr. Saunders had a strong knowledge of the healthcare industry, having managed portfolio companies including UpToDate, Inc— a medical research service for physicians and hospitals. He currently served as a Trustee of the Cold Spring Harbor Laboratory, which has been home to eight Nobel Prize winners and has been consistently ranked as the No. 1 scientific research institution worldwide for its molecular biology and genetic research impact, as measured by science publisher Thomson Reuters.

Throughout his laudable career, Mr. Saunders had been involved in some of the most noteworthy financial transactions in history. These include, raising $3.8 billion of common equity for AT&T during an eighteen month period beginning in 1981, the largest amount of equity raised for a single company at the time. The underwriters’ option, known as the “Greenshoe”, was employed for the first time in a Fortune 100 company equity offering and has become a standard feature of public equity offerings. In 1980, Mr. Saunders managed the initial public offering (IPO) of Apple Computer. He led the team providing financial advice to AT&T on its $150 billion divestiture of the Bell System operating companies in 1984, the largest restructuring in history. This divestiture was the precursor to the present structure of the telecommunications industry in the United States.

Mr. Saunders’ philanthropic interests focused principally on higher education, historic preservation and the arts. He was a member of the Trustees’ Council of the National Gallery of Art in Washington, DC. He was the former chairman of the University of Virginia Darden School Foundation. He had been a member of the Boards of Visitors of the University of Virginia and the Virginia Military Institute. From 1995-2000, he was the National Co-Chairman of the University of Virginia’s $1.4 billion capital campaign.

Mr. Saunders received his BSEE from the Virginia Military Institute in 1958 and an MBA from the University of Virginia Darden School in 1967.

Mr. Saunders passed away September 9, 2022. VitalConnect honors his memory and commitment to innovation. He was the VitalConnect Lead Director from 2014 to 2023.